
Pharmacally
Acquisition
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Acquisition
Mergers & AcquisitionsChiesi Seals a Strategic Win with $1.9B KalVista AcquisitionChiesi Group will acquire KalVista Pharmaceuticals in a $1.9 billion deal, adding the first oral on-demand treatment for Hereditary Angioedema and strengthening its rare disease portfolio.Fact-Checked
Mergers & AcquisitionsBoehringer and Zai Lab Sharpen a Two-Edge Strategy to Cut Through DLL3 TumorsBoehringer Ingelheim and Zai Lab are testing a dual DLL3-targeting combination of obrixtamig and zocilurtatug pelitecan in a Phase Ib/II study for ES-SCLC and NECs, aiming to improve…Fact-Checked
Mergers & AcquisitionsGilead Bolsters ADC Strategy with Tubulis Acquisition Worth Up to $5BGilead Sciences, Inc. agreed to acquisition of Tubulis GmbH, adding clinical-stage ADCs led by TUB-040 in Phase 1b/2 for ovarian cancer and NSCLC, plus next-generation conjugation platforms, in…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.